ArticleJournal of translational medicine2026
Gypenosides inhibit melanoma proliferation, migration and enhance the anti-tumor immunity of CD8
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMelanoma is a highly aggressive cancer that often creates a profoundly immunosuppressive tumor microenvironment and tends to invade and metastasize early in the disease process. Gypenosides have been reported to exhibit anti-melanoma activity, yet its underlying mechanisms remain incompletely understood. The objective is to assess the role of gypenosides in anti-melanoma and to further investigate its pharmacological effects.
methodsA systematic evaluation of the anti-melanoma efficacy and safety of gypenosides was established by in vitro and in vivo experiments. Transcriptome sequencing was used to screen potential molecular targets, and co-culture and flow cytometry were applied to explore the effects of gypenosides, aiming to elucidate the underlying mechanisms.
resultsBoth in vitro and in vivo experiments have observed that gypenosides, as well as their active monomers gypenoside-XLIX and gypenoside-LI, significantly inhibit melanoma cell proliferation by inducing G0/G1 cell cycle arrest, and inhibit migration through downregulating MMP2/MMP9. RNA-sequencing combined with gene expression perturbation identified ETV5 as the key mediator of the anti-tumor activity of gypenosides. Additionally, gypenosides downregulate the expression of PD-L1 via ETV5 in tumor cells, thereby promoting the activation of tumor-infiltrating CD8+ T cells and enhancing CD8+ T cell-mediated anti-melanoma immunity. In mouse tumor models, gypenosides demonstrate potent efficacy in inhibiting melanoma growth and lung metastasis, and exhibit a favorable safety profile.
conclusionGypenosides and its active monomers gypenoside-XLIX and gypenoside-LI inhibit the proliferation and migration of melanoma, suppress the upregulation of ETV5-mediated increase in PD-L1 expression, and enhance the anti-tumor immunity of CD8+ T cells and promote the release of cytokines. These findings indicate that gypenosides may have valuable applications in the clinical treatment of melanoma and provide a useful theoretical basis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.